Form 4: Cocrystal Pharma Director Steven Rubin Acquires Shares Through Restricted Stock Units

Director Steven Rubin acquired 18,957 shares of Cocrystal Pharma through restricted stock units, increasing his direct holdings.

Summary

• On October 9, 2024, Steven Rubin, a director of Cocrystal Pharma, acquired 18,957 shares of common stock through the vesting of restricted stock units (RSUs).
• Following the transaction, Rubin directly owns 2,660,242 shares of Cocrystal Pharma.
• One half of the RSUs are fully vested, with the balance vesting in eight equal quarterly installments on the last day of each quarter commencing with the quarter ending September 30, 2025, subject to continued services for the Company as of each applicable vesting date.
• The RSUs were granted under the Issuer's 2015 Equity Incentive Plan and will vest in full upon a Change of Control as defined in such Plan.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock acquisition through vested RSUs. While insider ownership can be a positive signal, this is part of a pre-existing compensation plan.

Positives

• The acquisition of shares by a director can be seen as a positive sign, indicating confidence in the company's future prospects.

Future Outlook

The remaining RSUs will continue to vest in equal quarterly installments until September 30, 2025, subject to continued service.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the ownership changes of company insiders.

Stakeholder Impact

• The transaction increases the director's stake in the company, aligning his interests with those of other shareholders.

Key Dates